Conditions Converging For More M&A In Korean Pharma, Biotech
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
You may also be interested in...
Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.
With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.
South Korean medical product manufacturer BioGenetics, which has recently diversified into the biopharma business and entered alliances for novel anticancer drugs, aims to further beef up its pharma activities through the acquisition of Kyung Nam Pharm, which will secure distribution networks at home and abroad.